Table 1.
Baseline characteristics of 337 patients (including prognostic significance of the selected variables)
| Variable | Categories (No) | 3-year OS |
p-value (HR) |
3-year LRC |
p-value (HR) |
3-year MFS |
p-value (HR) |
|
|---|---|---|---|---|---|---|---|---|
| Age | < 65 | 159 | 21.3% | 0.02 | 57.5% | 0.40 | 36.3% | 0.23 |
| ≥65 | 178 | 16.1% | (1.34) | 54.0% | (1.21) | 40.3% | (0.81) | |
| Sex | M | 260 | 16.1% | 0.02 | 55.6% | 0.64 | 36.7% | 0.23 |
| F | 77 | 29.6% | (0.70) | 57.5% | (0.88) | 44.9% | (0.77) | |
| Histology | squamous | 206 | 14.8% | 0.02 * | 49.1% | 0.02 * | 41.2% | 0.23 * |
| adeno | 50 | 31.9% | (0.64) | 82.4% | (0.36) | 35.5% | (1.32) | |
| NOS | 81 | 24.6% | 52.3% | 32.8% | ||||
| T stage | 1–2 | 120 | 22.2% | < 0.001 | 62.4% | 0.04 | 42.9% | 0.02 |
| 3–4 | 201 | 16.6% | (1.61) | 48.3% | (1.61) | 36.8% | (1.57) | |
| N/A | 16 | |||||||
| N stage | 0–1 | 71 | 17.6% | 0.86 | 64.2% | 0.13 | 36.9% | 0.36 |
| 2–3 | 250 | 20.2% | (1.03) | 54.2% | (1.59) | 41.4% | (1.23) | |
| N/A | 16 | |||||||
| M stage | 0 | 260 | 21.2% | < 0.001 | 55.2% | 0.95 | 47.9% | < 0.001 |
| 1 | 68 | 8.6% | (1.78) | 65.7% | (1.02) | 0.0% | (8.7) | |
| N/A | 9 | |||||||
| ZUBROD | 0–1 | 306 | 19.6% | 0.015 | 55.6% | 0.23 | 37.4% | 0.43 |
| 2–3 | 31 | 19.4% | (1.72) | 61.3% | (1.60) | 60.9% | (0.72) | |
| Radiotherapy | < 60 Gy | 189 | 10.1% | < 0.001 | 49.6% | 0.004 | 19.4% | < 0.001 |
| ≥60 Gy | 148 | 30.6% | (0.38) | 61.5% | (0.52) | 35.9% | (0.29) | |
| Smoking status | never | 22 | 61.6% | < 0.001 | 81.5% | 0.04 | 46.8% | 0.21 |
| ever | 314 | 17.3% | (3.66) | 53.2% | (4.45) | 38.2% | (1.54) | |
| Chemotherapy | no | 124 | 12.7% | < 0.001 | 53.5% | 0.02 | 42.0% | 0.009 |
| yes | 213 | 23.7% | (0.43) | 57.1% | (0.55) | 28.8% | (0.61) | |
*comparison between squamous cell cancer and adenocarcinoma
Significance (p-value, HR) refers to the univariable Cox regression analysis, 3-year OS, LRC and MFS in the respective groups are also presented